The calm before the storm ?

The next 2 weeks are likely to be a little more subdued in the lead-up, to what should be an incredibly busy September for Mesoblast.

FDA approval for RYONCIL appears close to certain, this will likely happen earlier than the 30th of September cut off date and I’m predicting the first week of that month. 

 The readouts for a couple of potential blockbusters to treat chronic heart failure and chronic lower back pain were due mid-year but now appear likely sometime in September too. 

Personally, I’d be surprised if we didn’t see the price of MSB shares gradually rise over the remainder of the month as news filters through to more investors than ever before. 

News stories are already beginning to appear which paint MSB in a more positive light than stories in years past. Many journalists have taken pot-shots at Mesoblast over the years, with the most common complaints being the number of capital raisings conducted and accusations of MSB being a company that over-promises and under-delivers.  

Today, Mesoblast is holding $129M USD in cash which appears to be plenty to see it through the next 18 months or so, but more importantly than that, Mesoblast may be about to deliver in an extraordinarily big way. 

In case you hadn’t noticed, there’s a rather large crisis consuming the attention and financial resources of people and their governments globally, at an alarming rate. Could Mesoblast be catapulted to global headlines for delivering the world’s most effective treatment of COVID-19s sickest patients? We’re about to find out. 

Categories: Uncategorized

1 Comment

ddwn · August 23, 2020 at 12:42 pm

Agreed – and I share your sentiments.

We often forget that we are all early birds on Mesoblast here.
And being early birds we had to research and find out a lot of information on Mesoblast.

But, in the next few weeks – the spotlight is going to be shined on Mesoblast with a combination of first FDA approved MSC product in the US and news on Covid-19 ARDS.

Mesoblast is hardly known in Australia and is still considered as a spec stock. Mesoblast is less know in the US.

So bring those two news above and we’ll have fireworks.
I believe if you have a chance to top up, then do it soon.
As the SP is about to surge significantly upwards when these news are announced.

Leave a Reply

Avatar placeholder

Your email address will not be published. Required fields are marked *